CCL

Összesen 5 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM123875
035-os BibID:(Scopus)85201771588 (WoS)001308121100001
Első szerző:Espinosa-Ortega, Fabricio
Cím:Autoantibodies and damage in patients with idiopathic inflammatory myopathies : a longitudinal multicenter study from the MYONET international network / Espinosa-Ortega Fabricio, Lodin Karin, Dastmalchi Maryam, Vencovsky Jiri, Diederichsen Louise P., Shinjo Samuel Katsuyuki, Danieli Maria Giovanna, Selva-O'Callaghan Albert, de Visser Marianne, Griger Zoltan, Ceribelli Angela, Gómez-Martin Diana, Andersson Helena, Mercado Mónica Vázquez-Del, Chinoy Hector, Lilleker James B., New Paul, Krogh Niels S., Lundberg Ingrid E., Alexanderson Helene, MYONET Registry Study Group
Dátum:2024
ISSN:0049-0172
Megjegyzések:Objective To study the trajectories of changes in damage over time and explore associations with autoantibody defined subgroups using a large international cohort of patients with idiopathic inflammatory myopathies (IIM). Methods Data from the MYONET registry, including patients who were tested for autoantibodies and had at least one assessment of damage using the Myositis Damage Index (MDI), were analyzed. Patients were sub-grouped according to their autoantibody profiles (myositis-specific, myositis-associated, or seronegative). The index date was defined as the time point for the first registered MDI assessment. The longitudinal trajectories of damage with autoantibody status as the main predictor were analyzed using linear mixed models. Results A total of 757 adult patients were included in this study. Each year of disease duration since diagnosis had an estimated MDI score increase of 0.16 units for the seronegative group (reference). Compared with the seronegative group as reference, patients with dermatomyositis-specific autoantibodies developed less damage per year of follow-up since diagnosis (average 0.08 less score, P = 0.04), whereas patients with anti-PM/Scl autoantibodies developed more damage per year of follow-up since diagnosis (average 0.28 higher score, P = 0.03) independent of sex and age at diagnosis. The seronegative subgroup and the immune-mediated necrotizing myopathy autoantibody subgroup had the strongest correlation between severity of muscle damage and HAQ-DI scores at five years of follow-up, rho=0.84, P < 0.001 and rho=0.72, P < 0.001, respectively. Conclusion Our study is the first to describe patterns and trajectories of change in damage over time in relation to autoantibody defined subgroups in a large international multicenter cohort of patients with IIM. Patients with anti-PM/Scl scored a greater extent of damage, whereas patients with dermatomyositis-specific antibodies had less damage than seronegative patients. Severity in muscle damage had moderate to strong correlation with functional disability among the IMNM and seronegative subgroups with lower correlations for the other subgroups. These findings suggest that autoantibodies may be useful predictors of long-term damage.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Autoantibodies
Dermatomyositis
Inflammatory myopathies
Organ damage
Myositis
Megjelenés:Seminars In Arthritis And Rheumatism. - 68 (2024), p. 1-10.-
További szerzők:Lodin, Karin Dastmalchi, Maryam Vencovsky, Jiri Diederichsen, Louise Pyndt Shinjo, Samuel Katsuyuki Danieli, Maria Giovanna Selva-O'Callaghan, Albert de Visser, Marianne Griger Zoltán (1979-) (belgyógyász, allergológus és klinikai immunológus, reumatológus) Ceribelli, Angela Gómez-Martin, Diana Andersson, Helena Mercado, Mónica Vázquez-Del Chinoy, Hector Lilleker, James B. New, Paul Krogh, Niels Steen Lundberg, Ingrid Alexanderson, Helene MYONET Registry
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

2.

001-es BibID:BIBFORM105749
035-os BibID:(scopus)85139571711 (wos)000840395200001
Első szerző:Fazal, Zoha Zahid
Cím:COVAD survey 2 long-term outcomes : unmet need and protocol / Fazal Zoha Zahid, Sen Parikshit, Joshi Mrudula, Ravichandran Naveen, Lilleker James B., Agarwal Vishwesh, Kardes Sinan, Kim Minchul, Day Jessica, Makol Ashima, Milchert Marcin, Gheita Tamer, Salim Babur, Velikova Tsvetelina, Gracia-Ramos Abraham Edgar, Parodis Ioannis, Nikiphorou Elena, Tan Ai Lyn, Chatterjee Tulika, Cavagna Lorenzo, Saavedra Miguel A., Shinjo Samuel Katsuyuki, Ziade Nelly, Selva-O'Callaghan Albert, Nune Arvind, Knitza Johannes, Kuwana Masataka, Gutiérrez Carlos-Enrique Toro, Caballero-Uribe Carlo Vinicio, Dey Dzifa, Distler Oliver, Chinoy Hector, Agarwal Vikas, Aggarwal Rohit, Gupta Latika, COVAD Study Group
Dátum:2022
ISSN:0172-8172 1437-160X
Megjegyzések:Vaccine hesitancy is considered a major barrier to achieving herd immunity against COVID-19. While multiple alternative and synergistic approaches including heterologous vaccination, booster doses, and antiviral drugs have been developed, equitable vaccine uptake remains the foremost strategy to manage pandemic. Although none of the currently approved vaccines are live-attenuated, several reports of disease flares, waning protection, and acute-onset syndromes have emerged as short-term adverse events after vaccination. Hence, scientific literature falls short when discussing potential long-term effects in vulnerable cohorts. The COVAD-2 survey follows on from the baseline COVAD-1 survey with the aim to collect patient-reported data on the long-term safety and tolerability of COVID-19 vaccines in immune modulation. The e-survey has been extensively pilot-tested and validated with translations into multiple languages. Anticipated results will help improve vaccination efforts and reduce the imminent risks of COVID-19 infection, especially in understudied vulnerable groups.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Autoimmune diseases
COVID-19
Long-term adverse effects
Registries
Vaccination
Megjelenés:Rheumatology International. - 42 : 12 (2022), p. 2151-2158. -
További szerzők:Sen, Parikshit Joshi, Mrudula Ravichandran, Naveen Lilleker, James B. Agarwal, Vishwesh Kardes, Sinan Kim, Minchul Day, Jessica Makol, Ashima Milchert, Marcin Gheita, Tamer A. Salim, Babur Velikova, Tsvetelina Gracia-Ramos, Abraham Edgar Parodis, Ioannis Nikiphorou, Elena (reumatológus) Tan, Ai Lyn Chatterjee, Tulika Cavagna, Lorenzo Saavedra, Miguel A. Shinjo, Samuel Katsuyuki Ziade, Nelly Selva-O'Callaghan, Albert Nune, Arvind Knitza, Johannes Kuwana, Masataka Gutiérrez, Carlos-Enrique Toro Caballero-Uribe, Carlo Vinicio Dey, Dzifa Distler, Oliver Chinoy, Hector Agarwal, Vikas Aggarwal, Rohit Gupta, Latika Nagy-Vincze Melinda (1985-) (orvos) Griger Zoltán (1979-) (belgyógyász, allergológus és klinikai immunológus, reumatológus) COVAD Study Group
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

3.

001-es BibID:BIBFORM133188
035-os BibID:(wos)001611752600001
Első szerző:Gono, Takahisa
Cím:Analytical performance of commercial myositis-specific autoantibody tests evaluated against immunoprecipitation assays as a reference standard : a systematic review and meta-analysis / Gono Takahisa, Gil-Vila Albert, Selva-O'Callaghan Albert, van Royen-Kerkhof Annet, Vincze Anett, Mecoli Christopher, Gómez-Martín Diana, Hamann Dörte, Conticini Edoardo, Griger Zoltán, Torres-Ruiz Jose Jiram, Pauling John D., Chinoy Hector, Gupta Latika, Bodoki Levente, Nasir Noreen, Chavan Pallavi Pimpale, Khubchandani Raju, Ernesto Trallero-Araguás, Hamaguchi Yasuhito, Rider Lisa G., Aggarwal Rohit, Tansley Sarah, Rönnelid Johan, Kuwana Masataka, McHugh Neil J., International Myositis Assessment and Clinical Studies Group (IMACS), Myositis Autoantibody Scientific Interest Group (SIG) Study
Dátum:2025
ISSN:0049-0172
Megjegyzések:Objective: To evaluate the analytical performance of commercial myositis-specific autoantibody (MSA) assays against immunoprecipitation (IP) assays. Methods: A systematic literature search was conducted in PubMed, Web of Science, and Scopus through July 2024. Data were extracted on study design, participant characteristics, index tests, and 2 ? 2 contingency tables for diagnostic performance. Study quality was assessed using the QUADAS-2 tool. Sensitivity and specificity were calculated for each dataset and presented as paired forest plots and summary receiver operating characteristic (SROC) curves. A hierarchical SROC model was used to estimate pooled sensitivity and specificity for meta-analysis. Results: Of 3156 articles, 23 met inclusion criteria and were judged to have low risk of bias across all QUADAS-2 domains. The most frequently evaluated commercial assay was the line blot assay (LBA; 16 studies), followed by enzyme immunoassay (EIA; 9 studies). In the meta-analyses, the highest pooled sensitivity was observed for anti-MDA5 with EIA (95.7 %), followed by anti-SAE with LBA (88.3 %), anti-PL-12 with LBA (87.2 %), and anti-Jo-1 and anti-MDA5 with LBA (82.8 %). Lower sensitivities were observed for anti-Mi-2 (67.4 %), anti-NXP2 (69.7 %), and anti-TIF1-? (63.8 %) with LBA. Pooled specificity ranged from 94.7 % to 99.3 % across MSA assays, but a false-positive result was a common concern for LBA, except for anti-EJ. Conclusion: False-positive and false-negative results remain a significant challenge in the use of commercial MSA assays.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Autoantibody
Diagnostic accuracy test
Meta-analysis
Myositis
Systematic review
Megjelenés:Seminars In Arthritis And Rheumatism. - 75 (2025), p. 1-11. -
További szerzők:Gil-Vila, Albert Selva-O'Callaghan, Albert van Royen-Kerkhof, Annet Vincze Anett (1993-) (orvos) Mecoli, Christopher Gómez-Martin, Diana Hamann, Dörte Conticini, Edoardo Griger Zoltán (1979-) (belgyógyász, allergológus és klinikai immunológus, reumatológus) Torres-Ruiz, Jiram Pauling, John D. Chinoy, Hector Gupta, Latika Bodoki Levente (1986-) (PhD hallgató) Nasir, Noreen Chavan, Pallavi Pimpale Khubchandani, Raju Ernesto, Trallero-Araguás Hamaguchi, Yasuhito Rider, Lisa G. Aggarwal, Rohit Tansley, Sarah Rönnelid, Johan Kuwana, Masataka McHugh, Neil International Myositis Assessment and Clinical Studies Group Myositis Autoantibody Scientific Interest Group (SIG) Study
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

4.

001-es BibID:BIBFORM122935
035-os BibID:(scopus)85191656275 (wos)001195980800001
Első szerző:Oldroyd, Alexander
Cím:Author Correction : International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening: an International Myositis Assessment and Clinical Studies Group (IMACS) initiative / Oldroyd Alexander G. S., Callen Jeffrey P., Chinoy Hector, Chung Lorinda, Fiorentino David, Gordon Patrick, Machado Pedro M., McHugh Neil, Selva-O'Callaghan Albert, Schmidt Jens, Tansley Sarah L., Vleugels Ruth Ann, Werth Victoria P., International Myositis Assessment and Clinical Studies Group Cancer Screening Expert Group, Aggarwal Rohit
Dátum:2024
ISSN:1759-4790 1759-4804
Megjegyzések:In the version of the article initially published, two affiliations for Jens Schmidt were missing and have now been added as affiliations 16 and 17 in the HTML and PDF versions of the article: Department of Neurology and Pain Treatment, Immanuel Klinik Rüdersdorf, University Hospital of the Brandenburg Medical School Theodor Fontane, Rüdersdorf bei Berlin, Germany and Faculty of Health Sciences Brandenburg, Brandenburg Medical School Theodor Fontane, Rüdersdorf bei Berlin, Germany. ? Springer Nature Limited 2024.
Tárgyszavak:Orvostudományok Klinikai orvostudományok hozzászólás
folyóiratcikk
article
cancer screening
clinical study
controlled study
diagnosis
drug therapy
female
Germany
human
idiopathic inflammatory myopathy
malignant neoplasm
myositis
rheumatology
adult
erratum
male
Megjelenés:Nature Reviews Rheumatology. - 20 : 5 (2024), p. 315. -
További szerzők:Callen, Jeffrey P. Chinoy, Hector Chung, Lorinda Fiorentino, David Gordon, Patrick Machado, Pedro M. McHugh, Neil Selva-O'Callaghan, Albert Schmidt, Jens Tansley, Sarah Vleugels, Ruth Ann Werth, Victoria P. Aggarwal, Rohit Griger Zoltán (1979-) (belgyógyász, allergológus és klinikai immunológus, reumatológus) Nagy-Vincze Melinda (1985-) (orvos) International Myositis Assessment and Clinical Studies Group Cancer Screening Expert Group
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

5.

001-es BibID:BIBFORM116491
035-os BibID:(wos)001103143700001 (scopus)85176609027
Első szerző:Oldroyd, Alexander
Cím:International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening : an International Myositis Assessment and Clinical Studies Group (IMACS) initiative / Alexander G. S. Oldroyd, Jeffrey P. Callen, Hector Chinoy, Lorinda Chung, David Fiorentino, Patrick Gordon, Pedro M. Machado, Neil McHugh, Albert Selva-O'Callaghan, Jens Schmidt, Sarah L. Tansley, Ruth Ann Vleugels, Victoria P. Werth, International Myositis Assessment and Clinical Studies Group Cancer Screening Expert Group, Rohit Aggarwal
Dátum:2023
ISSN:1759-4790 1759-4804
Megjegyzések:Adult-onset idiopathic inflammatory myopathy (IIM) is associated with an increased cancer risk within the 3 years preceding and following IIM onset. Evidence- and consensus-based recommendations for IIM-associated cancer screening can potentially improve outcomes. This International Guideline for IIM-Associated Cancer Screening provides recommendations addressing IIM-associated cancer risk stratification, cancer screening modalities and screening frequency. The international Expert Group formed a total of 18 recommendations via a modified Delphi approach using a series of online surveys. First, the recommendations enable an individual patient's IIM-associated cancer risk to be stratified into standard, moderate or high risk according to the IIM subtype, autoantibody status and clinical features. Second, the recommendations outline a 'basic' screening panel (including chest radiography and preliminary laboratory tests) and an 'enhanced' screening panel (including CT and tumour markers). Third, the recommendations advise on the timing and frequency of screening via basic and enhanced panels, according to risk status. The recommendations also advise consideration of upper or lower gastrointestinal endoscopy, nasoendoscopy and 18F-FDG PET-CT scanning in specific patient populations. These recommendations are aimed at facilitating earlier IIM-associated cancer detection, especially in those who are at a high risk, thus potentially improving outcomes, including survival.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Nature Reviews Rheumatology. - 19 : 12 (2023), p. 805-817. -
További szerzők:Callen, Jeffrey P. Chinoy, Hector Chung, Lorinda Fiorentino, David Gordon, Patrick Machado, Pedro M. McHugh, Neil Selva-O'Callaghan, Albert Schmidt, Jens Tansley, Sarah Vleugels, Ruth Ann Werth, Victoria P. Aggarwal, Rohit Griger Zoltán (1979-) (belgyógyász, allergológus és klinikai immunológus, reumatológus) Nagy-Vincze Melinda (1985-) (orvos) International Myositis Assessment and Clinical Studies Group Cancer Screening Expert Group
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1 
Corvina könyvtári katalógus v10.11.18-SNAPSHOT © 2024 Monguz kft. Minden jog fenntartva.